- Home
- CURI vs ABOS Comparison
CURI vs ABOS Comparison
Compare CURI & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CURI | ABOS |
|---|---|---|
| Founded | N/A | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.0M | 197.9M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CURI | ABOS |
|---|---|---|
| Price | $2.91 | $2.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $5.83 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 739.8K | 358.3K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | ★ 10.36% | N/A |
| EPS Growth | ★ 54.17 | N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $78,043,000.00 | N/A |
| Revenue This Year | $14.91 | N/A |
| Revenue Next Year | $12.91 | N/A |
| P/E Ratio | $24.25 | ★ N/A |
| Revenue Growth | ★ 9.52 | N/A |
| 52 Week Low | $2.30 | $1.50 |
| 52 Week High | $5.38 | $3.60 |
Technical Indicators
Market Signals| Indicator | CURI | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 52.99 | 37.61 |
| Support Level | $2.81 | $2.13 |
| Resistance Level | $2.97 | $2.42 |
| Average True Range (ATR) | 0.12 | 0.18 |
| MACD | 0.02 | -0.07 |
| Stochastic Oscillator | 57.27 | 16.36 |
Price Performance
Historical ComparisonAbout CURI CuriosityStream Inc.
CuriosityStream Inc is a media and entertainment company. It offers premium video programming across the principal categories of factual entertainment, including science, history, society, nature, lifestyle, and technology. The firm's products and services are Direct to Consumer Business, Partner Direct Business, Bundled Distribution, Content Licensing, and Others. The majority of the revenue comes from the direct business and Content licensing. Geographically, the company generates the majority of its revenue from the United States.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.